Skip to content

Interest Income at other companies

CTO
Citius Oncology, Inc.CTOR
$43.72K+381%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
$1.78M+240%
Janux Therapeutics logo
Janux TherapeuticsJANX
$9.85M-13.5%
Vera Therapeutics logo
Vera TherapeuticsVERA
$6.36M-8.0%

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeOther.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s interest income?
TuHURA Biosciences, Inc. (HURA) reported interest income of $21.28K in Q1 2026.
How has TuHURA Biosciences, Inc.'s interest income changed year-over-year?
TuHURA Biosciences, Inc.'s interest income decreased by 78.7% year-over-year, from $100.1K to $21.28K.
What is the long-term trend for TuHURA Biosciences, Inc.'s interest income?
Over 2 years (2023 to 2025), TuHURA Biosciences, Inc.'s interest income has grown at a 23.3% compound annual growth rate (CAGR), from $89.67K to $136.23K.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.